Katie Adams / medcitynews - Eli Lilly made good on its threat to withhold 340B drug discounts from hospitals that refused to submit claims data. Hospital groups are calling the policy unlawful, arguing that the company has no legal authority to create its own compliance requirements…
AI Summary: Eli Lilly has begun denying 340B program discounts to participating hospitals after issuing an ultimatum, prompting sharp criticism from safety-net providers. Hospitals say the move will squeeze margins and threaten patient access to affordable medicines. The dispute centers on manufacturer discount eligibility and contract terms as providers scramble to quantify the financial hit.
fiercehealthcare - The nonpartisan office is seeking more information on the law’s impact on healthcare prices, network participation, ownership structures and more.
AI Summary: The Congressional Budget Office has called for additional research into the No Surprises Act, urging deeper study of the law’s unintended consequences on pricing, provider networks and patient costs. Federal agencies and stakeholders are being pressed to produce better evidence so policymakers can evaluate whether the law’s goals align with real-world effects.


StackHealth RSS
StackHealth Time Machine
More StackHealth
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.